Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aprea's treatment of acute myeloid leukemia (AML) has been recommended an orphan drug status by the The European Medicines Agency (EMEA). The treatment, at present, is subject to a Phase I clinical study and a final decision from the European Commission concerning the status is anticipated in some weeks.
Subscribe to our email newsletter
Conny Bogentoft, CEO of Karolinska Development, said: “Aprea is developing a new class of anticancer drugs for the treatment of acute myelogenous leukemia, the most common acute leukemia affecting adults which is currently lacking efficient treatment.
“An orphan drug status would significantly shorten the development time, lower development costs and, if approved, extend market exclusivity to the benefit of affected patients, Aprea and Karolinska Development.”
Karolinska Development manages a portfolio of life science companies in Europe. Since 2003, it has built a portfolio of around 40 companies. Among the company’s projects, 12 compounds are undergoing clinical trials. The portfolio also includes a total of 19 other products.